Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin + ethambutol with rifampicin versus clofazimine for pulmonary MAC disease
NL-OMON45792Phase 3Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2016
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azithromycin, ethambutol, rifampicin and clofazimine in Mycobacterium avium lung disease (2 arms), sponsored by Radboud University Medical Center. Started Apr 2016; status: active, not recruiting.
02
Drugs
azithromycinethambutolrifampicinclofazimine
03
Conditions
Mycobacterium avium lung disease
Beyond the preview
Go deeper on NL-OMON45792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45792.